Security National Bank of SO Dak Purchases 226 Shares of Johnson & Johnson (NYSE:JNJ)

Security National Bank of SO Dak lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,331 shares of the company’s stock after purchasing an additional 226 shares during the period. Johnson & Johnson accounts for approximately 1.5% of Security National Bank of SO Dak’s investment portfolio, making the stock its 22nd biggest holding. Security National Bank of SO Dak’s holdings in Johnson & Johnson were worth $2,651,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Pacifica Partners Inc. grew its position in shares of Johnson & Johnson by 17.1% during the 4th quarter. Pacifica Partners Inc. now owns 35,046 shares of the company’s stock worth $5,047,000 after purchasing an additional 5,111 shares in the last quarter. Fiduciary Financial Group LLC boosted its stake in shares of Johnson & Johnson by 5.8% in the fourth quarter. Fiduciary Financial Group LLC now owns 4,370 shares of the company’s stock valued at $621,000 after buying an additional 240 shares during the period. Wynn Capital LLC grew its position in Johnson & Johnson by 1.4% during the fourth quarter. Wynn Capital LLC now owns 12,647 shares of the company’s stock worth $1,829,000 after buying an additional 178 shares in the last quarter. Accurate Wealth Management LLC increased its stake in Johnson & Johnson by 8.4% during the 4th quarter. Accurate Wealth Management LLC now owns 23,214 shares of the company’s stock worth $3,298,000 after acquiring an additional 1,806 shares during the period. Finally, SeaCrest Wealth Management LLC raised its holdings in Johnson & Johnson by 1.5% in the 4th quarter. SeaCrest Wealth Management LLC now owns 25,087 shares of the company’s stock valued at $3,628,000 after acquiring an additional 374 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. The Goldman Sachs Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price target for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $169.00 to $153.00 in a research report on Tuesday. Finally, Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Trading Up 2.1%

Shares of JNJ stock opened at $149.40 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock’s fifty day simple moving average is $156.56 and its 200 day simple moving average is $154.00. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $359.47 billion, a P/E ratio of 22.47, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.48%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is 57.84%.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.